When Medicine Treats the Wrong Problem: What 35,000 Stroke Patients Reveal About Our Categories
The Assumption
For decades, the logic seemed airtight: strokes happen when arteries narrow and block, cutting off blood flow to the brain. Treatment followed naturally: aspirin, blood thinners, anti-clotting drugs to prevent the fatty deposits that cause blockages. The approach made sense for most strokes. For approximately 35,000 people across the UK each year who experience lacunar strokes, this logic has guided their care, according to researchers at the University of Edinburgh. It has also been fundamentally wrong.
Stroke is the fourth leading cause of death in the UK and the leading cause of complex adult disability, per the UK Dementia Research Institute. Every day, 240 people survive stroke in the UK, according to the same source. A quarter of those strokes are lacunar, a type that occurs deep in the brain's small blood vessels. Until now, medicine has treated them like any other stroke, assuming the same mechanism and prescribing the same drugs.
The Opposite Pattern
A study published by researchers at the University of Edinburgh and the UK Dementia Research Institute analyzed 229 patients who had experienced either a lacunar or mild non-lacunar stroke. What they found inverts the standard model: lacunar strokes are caused by enlargement and widening of arteries in the brain, not by blockage of arteries by fatty deposits, according to the research team. The arteries weren't narrowing. They were failing in the opposite direction.
Patients with widening arteries were more than four times more likely to have a lacunar stroke, the study found. Meanwhile, narrowing of large arteries was more commonly seen in other types of stroke, not lacunar stroke, per the researchers. The mechanism isn't blockage or clotting. It's structural failure of a different kind entirely, a weakening and expansion of vessel walls deep in the brain where the smallest arteries branch and rebranch.
Prof Joanna Wardlaw, a professor of applied neuroimaging at the University of Edinburgh and group leader at the UK Dementia Research Institute, led the research. The imaging revealed what previous studies had missed: a distinct pathology hiding beneath a shared diagnostic label. When an artery widens rather than narrows, the physics of blood flow changes. The vessel wall stretches thin. The tissue it feeds becomes vulnerable not to sudden blockage but to chronic underperfusion and rupture.
Why Aspirin Doesn't Work
Aspirin and other blood thinners are not as effective in preventing lacunar stroke, according to the study findings. This makes mechanical sense once you understand the underlying pathology. Blood thinners work by preventing clots from forming in narrowed arteries, where turbulent flow and fatty plaques create conditions for blockage. They target a problem of accumulation and obstruction.
But if the artery is widening, not narrowing, there's nothing for aspirin to prevent. The drug is solving for the wrong physics. It's like treating a burst pipe with a drain cleaner designed for clogs. The intervention doesn't match the failure mode. For decades, 35,000 patients annually have been prescribed medications based on their diagnostic category rather than their biological mechanism.
What Categories Hide
This isn't medical malpractice. It's what happens when diagnostic labels obscure the biological diversity beneath them. Medicine creates categories to make treatment decisions manageable: stroke, cancer, depression. These labels are useful, even necessary. But they're abstractions imposed on continuous biological variation. Sometimes the category groups together phenomena that only superficially resemble each other.
The psilocybin research published in Nature Communications offers a parallel case. A single dose of psilocybin can induce anatomical changes in the brain that are still apparent a month after taking the drug, according to the study. Within an hour of taking psilocybin, EEG revealed a surge in brain entropy in 28 healthy volunteers, per the research. A month later, DTI scans revealed a drop in diffusion along nerve tracts running from the front to the middle of the brain, the study found.
Those with the largest spike in brain entropy after psilocybin were most likely to report deeper psychological insight and better wellbeing a month later, according to the findings. Prof Robin Carhart-Harris, a neurologist at the University of California, San Francisco, worked on the research. The point isn't that psilocybin treats strokes. It's that different brain mechanisms require different interventions, even when surface symptoms look similar. The same principle applies across medicine: what we call depression or psychosis or stroke may encompass multiple distinct biological processes that happen to produce overlapping effects.
The Funding Gap
Less than 1% of total UK research funding is spent on stroke research, according to data from the UK Dementia Research Institute. This matters because discovering that lacunar strokes operate through arterial widening rather than narrowing required detailed imaging studies of the sort that only sustained research programs can produce. The University of Edinburgh team had to scan hundreds of patients and compare arterial structure across stroke types. That work takes time, equipment, and money.
Without adequate funding, medicine defaults to treating categories rather than mechanisms. The diagnostic label becomes the target. Everyone with "stroke" gets blood thinners because that's what works for most strokes, and there isn't enough research capacity to investigate whether subgroups might need something different. The result is 35,000 people annually receiving treatments that were never designed for their underlying pathology.
Biology Doesn't Respect Boundaries
Prof Daniel M Davis, head of life sciences at Imperial College London, has written about how biological systems resist the neat categories we impose on them. The lacunar stroke findings fit a pattern emerging across medical research: the more closely we look, the more we find that diagnostic labels group together distinct mechanisms. What we call one disease often turns out to be several.
This has implications beyond stroke treatment. It suggests that when a therapy works for some patients but not others with the "same" diagnosis, the problem may not be individual variation in drug response. It may be that we're grouping together people with fundamentally different conditions. The solution isn't better drugs for the category. It's better categories that reflect actual biological mechanisms.
The challenge is that mechanism-based medicine requires more research, more imaging, more molecular analysis. It requires funding that currently doesn't exist. Stroke kills and disables hundreds of thousands of people in the UK, yet receives less than 1% of research investment. We can't fix what we don't fund ourselves to understand. The lacunar stroke discovery reveals not just a treatment mismatch but a systems-level failure: medicine organized around categories that may not correspond to the biology underneath, and insufficient resources to investigate whether our abstractions match reality.
For the 240 people who survive stroke every day in the UK, the question isn't philosophical. It's whether the treatment they receive targets the actual mechanism that damaged their brain, or just the diagnostic label in their chart. The Edinburgh research suggests that for a quarter of stroke survivors, we've been treating the label while the mechanism went unaddressed. That's not a failure of individual doctors. It's what happens when our categories stop matching the biology, and we lack the research infrastructure to notice.
